TEL/AML1 Qualitative Test: Booking, Price, and Results
About TEL/AML1 Qualitative Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | ETV6-RUNX1 Qualitative PCR, TEL-AML1 Fusion Gene Test, t(12;21)(p13;q22) PCR, FISH t(12;21), LSI TEL/AML1, B-ALL Gene Fusion Profile |
| Sample Type | Bone marrow (sodium heparin tube) and peripheral blood (EDTA tube) |
| Fasting Required | No fasting required |
| Report Time | 12 days |
| Recommended For | Primarily children aged 1 to 15 years; males and females |
| Price | Starting at ₹4,800 |
What Is a TEL/AML1 Qualitative Test?
The TEL/AML1 Qualitative test is a specialised molecular test that detects a specific genetic change in the blood or bone marrow. It identifies the fusion of two genes, TEL (also called ETV6) and AML1 (also called RUNX1), which results from an exchange of genetic material between chromosomes 12 and 21. This test is primarily ordered for children when a doctor suspects a type of blood cancer called acute lymphoblastic leukaemia (ALL). It is also known as the ETV6-RUNX1 Qualitative PCR or the TEL-AML1 Fusion Gene Test.
What Does a TEL/AML1 Qualitative Test Measure?
This test uses a method called Real-Time PCR (polymerase chain reaction) to examine the genetic material in a sample. It looks for one specific abnormality and reports whether it is present or absent.
| What Is Detected | What It Means |
|---|---|
| TEL/AML1 (ETV6-RUNX1) fusion gene | A specific genetic rearrangement where parts of chromosomes 12 and 21 have swapped positions |
| t(12;21)(p13;q22) translocation | The chromosomal abnormality that creates the TEL/AML1 fusion gene, found in roughly 25% of childhood B-cell precursor ALL cases |
| Qualitative result | The test gives a "detected" or "not detected" answer; it does not measure the amount of the fusion gene present |
Why Is a TEL/AML1 Qualitative Test Done?
A doctor may order this test to investigate certain symptoms or to confirm a suspected diagnosis in a child. The test also plays a role at several stages, from initial diagnosis to tracking how well treatment is working.
Common Symptoms That May Require This Test
The following symptoms may lead a doctor to suspect leukaemia and order this test:
- Persistent or unexplained fever
- Unusual tiredness or constant fatigue
- Pale appearance or pallor
- Unexplained bruising or bleeding easily
- Frequent infections that do not resolve quickly
- Joint or limb pain with no clear cause
- Night sweats combined with weight loss
Conditions This Test Can Help Detect
This test helps identify or support the diagnosis of the following conditions:
- B-cell precursor acute lymphoblastic leukaemia (ALL), the most common childhood cancer linked to this genetic change
- Acute myeloid leukaemia (AML), where this fusion gene is occasionally present
- Risk stratification in paediatric leukaemia, helping doctors assess how the disease may progress
TEL/AML1 Qualitative Test for Chronic Disease Monitoring
For children already diagnosed with ETV6-RUNX1-positive leukaemia, this test plays an important role in tracking treatment response. It can detect minimal residual disease (MRD), which refers to the small number of cancer cells that may remain after treatment. The test may be repeated at specific points during treatment, such as at day 29 and day 79, to assess how well the therapy is working. If MRD levels remain above a certain threshold, the treating doctor may adjust the treatment plan accordingly.
How to Prepare and What to Expect
No special preparation is needed for this test, but there are a few practical points to keep in mind before attending the collection appointment.
Do You Need to Fast?
No. Fasting is not required for the TEL/AML1 Qualitative test. The child may eat and drink as normal before the appointment. Continue any regular medications unless the treating doctor advises otherwise.
Practical Tips Before Your Test
The following steps will help ensure a smooth experience:
- Bring a detailed clinical history, including symptoms, previous test results and family medical history, as this is required for the test.
- Carry the doctor's prescription, as it is typically mandatory for this type of specialised test.
- Inform the healthcare professional about all medications and supplements currently being taken.
- If a bone marrow sample is required, follow any specific pre-procedure instructions given by the treating physician.
- Help the child stay calm and comfortable before sample collection.
Step-by-Step Procedure
This test requires two sample types: peripheral blood and bone marrow. The collection steps for each are described below.
Peripheral Blood Collection:
- A trained phlebotomist cleans the skin over a vein, usually in the arm.
- A needle is used to collect approximately 3 ml of blood into a lavender-top EDTA tube.
- The needle is removed, and a small bandage or cotton swab is applied to the site.
- The sample is labelled and stored at 2 to 8 degrees Celsius for transport.
Bone Marrow Collection:
- A doctor performs the bone marrow collection, usually from the hip bone, under local anaesthesia or mild sedation.
- Approximately 3 ml of bone marrow is collected into a green-top sodium heparin tube.
- The sample is handled carefully and stored refrigerated (not frozen) before dispatch.
Both samples are sent to the laboratory, where Real-Time PCR is used to check for the presence of the TEL/AML1 fusion gene.
Factors That Can Affect Accuracy
- Poor sample quality due to improper collection technique
- Incorrect storage or transport conditions (samples must be refrigerated, not frozen)
- Timing of sample collection relative to ongoing treatment (post-treatment samples may give different readings)
- Laboratory technique and equipment calibration
Understanding Your TEL/AML1 Qualitative Test Results
Results from this test should always be reviewed by a qualified haematologist or oncologist. The table below shows how results are generally interpreted.
| Result | Interpretation |
|---|---|
| Not Detected (Negative) | The TEL/AML1 fusion gene was not found in the sample; this specific chromosomal change is absent |
| Detected (Positive) | The fusion gene is present, which is associated with B-cell precursor ALL and generally indicates a favourable prognosis in children, with high overall survival rates when treated appropriately |
A negative result does not rule out other types of leukaemia with different genetic abnormalities. Additional tests may be needed.
Disclaimer: These ranges are general guidelines. The doctor will interpret the results based on the age, health history and other factors. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
While this test detects a genetic abnormality rather than a modifiable marker, these general points apply to families managing a leukaemia diagnosis or monitoring after treatment:
- Attend all follow-up appointments with the treating haematologist or oncologist as scheduled.
- Maintain a balanced diet and adequate rest to support overall wellbeing during treatment.
- Seek genetic counselling if recommended to better understand what the test results mean for the child and the family.
Lupin Diagnostics TEL/AML1 Qualitative Test Price
The TEL/AML1 Qualitative test price at Lupin Diagnostics starts at ₹4,800. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this specialised test.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 4800 |
| CHENNAI | 4800 |
| HYDERABAD | 4800 |
| KOLKATA | 4800 |
| NAVI MUMBAI | 4800 |
| PUNE | 4800 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for the TEL/AML1 Qualitative test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
This test detects a specific genetic rearrangement, the fusion of the TEL (ETV6) and AML1 (RUNX1) genes, using Real-Time PCR technology. It is primarily used to support the diagnosis of B-cell precursor acute lymphoblastic leukaemia (ALL) in children. Doctors also use it to assess prognosis and monitor treatment response.
This test is primarily recommended for children, typically between the ages of 1 and 15 years, when a haematologist or oncologist suspects leukaemia based on symptoms or earlier test findings. It is ordered by a specialist, not as a routine screening test.
A positive result means the TEL/AML1 fusion gene was detected, which is strongly associated with certain types of childhood leukaemia. However, the result must be reviewed together with other clinical findings, blood counts and tests before a definitive diagnosis is made. Your doctor will guide you through next steps.
A negative result means the TEL/AML1 fusion gene was not found in the sample. This does not rule out other types of leukaemia that involve different genetic abnormalities. If symptoms persist, the doctor may order additional tests to investigate further.
A peripheral blood sample is taken from a vein in the arm, similar to a routine blood draw. The bone marrow sample is collected from the hip bone under local anaesthesia. The procedure is done by trained medical professionals and is designed to cause minimal discomfort.
The report is typically available within 12 days from the date of sample collection at Lupin Diagnostics. Turnaround times may occasionally vary depending on sample quality and scheduling. You will receive your report digitally once it is ready.
Yes. For children already diagnosed with ETV6-RUNX1-positive leukaemia, this test is an effective tool for monitoring minimal residual disease (MRD). It may be repeated at defined points during treatment to assess whether the therapy is reducing the number of abnormal cells as expected.
TEL/AML1 Qualitative Test: Booking, Price, and Results
